Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…
Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for presentation at the annual meeting of the American Society of Clinical Oncology. The post Grail’s Galleri…
CoPilotIQ said the merged company will allow customers to observe patients across the care continuum via one technology integration, one security audit, and simplified procurement
People who work in real-life emergency rooms have raved about how the new TV drama “The Pitt” accurately captures the complex dynamics of their workplaces and the medical details of their cases. Host Dan Weissmann talks with Alex Janke, an emergency medicine doctor and health policy researcher, about how the show stacks up against his…
ST. PAUL, Minn. — High school senior Joshua Yang understands sacrifice. When he was midway through 10th grade, his mom survived a terrible car crash. But her body developed tremors, and she lost mobility. After countless appointments, doctors diagnosed her with Parkinson’s disease, saying it was likely triggered by brain injuries sustained in the wreck….
Corvus, a Chicago-based startup aiming to simplify the surgical referrals process, announced its launch. The company’s AI platform helps healthcare teams manage inbound surgical referrals more efficiently, ensuring patients are routed to the right treatment while also optimizing operating room utilization. The post Mayo Clinic-Backed Corvus Launches to Fix the Surgical Referrals Process appeared first…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
This volume explores findings from the KFF-Washington Post Survey of Parents on views of childhood vaccines; how ACIP may have contributed to concerns about hepatitis B and COVID-19 vaccines; recent HHS warnings about alleged links between Tylenol use in pregnancy and autism; and AI-generated deepfakes impersonating doctors to sell products.
This brief estimates the number of current Marketplace enrollees with a mental health diagnosis to understand what changes in enrollment may mean for access to services. Among the 24.3 million Marketplace enrollees in 2025, over 4.4 million individuals are estimated to have at least one mental health diagnosis on a health care claim.
FDA approval of Icotyde covers the treatment of adults and adolescents with moderate-to-severe plaque psoriasis. This once-daily pill, developed by partners Johnson & Johnson and Protagonist Therapeutics, offers an easier dosing option compared to injectables and is projected to become a blockbuster seller across several immunological indications. The post J&J Gets FDA Nod for Plaque…